发明名称 Markers for preeclampsia
摘要 This document provides methods and materials related to determining whether or not a pregnant mammal (e.g., a pregnant human) has preeclampsia. For example, methods and materials related to the use of urinary podocytes to determine whether or not a pregnant human has preeclampsia are provided.
申请公布号 US9557342(B2) 申请公布日期 2017.01.31
申请号 US201514733521 申请日期 2015.06.08
申请人 Mayo Foundation for Medical Education and Research 发明人 Garovic Vesna D.
分类号 G01N33/74;G01N33/53;G01N33/80;G01N33/68 主分类号 G01N33/74
代理机构 Fish & Richardson P.C. 代理人 Fish & Richardson P.C.
主权项 1. A method for avoiding unnecessary treatment of preeclampsia, said method comprising: (a) contacting a urine sample collected from a pregnant human during gestational week 33.5±5.6, 34.1±4.2, 34.3±3.8, or 39.2±2.2 with an anti-podocin antibody under conditions that allow binding of said anti-podocin antibody to a podocyte or a fragment of said podocyte wherein, when said urine sample contains podocytes or fragments of said podocytes, anti-podocin antibody complexes comprising said anti-podocin antibody and said podocyte or a fragment of said podocyte are formed, (b) contacting a urine sample collected from said pregnant human during gestational week 33.5±5.6, 34.1±4.2, 34.3±3.8, or 39.2±2.2 with an anti-synaptopodin antibody under conditions that allow binding of said anti-synaptopodin antibody to a podocyte or a fragment of said podocyte wherein, when said urine sample contains podocytes or fragments of said podocytes, anti-synaptopodin antibody complexes comprising said anti-synaptopodin antibody and said podocyte or a fragment of said podocyte are formed, (c) detecting an absence of an elevated level of said anti-podocin antibody complexes in step (a) as compared to corresponding urine levels from pregnant humans lacking preeclampsia, (d) detecting an absence of an elevated level of said anti-synaptopodin antibody complexes in step (b) as compared to corresponding urine levels from pregnant humans lacking preeclampsia, and (e) proceeding with treatment of said pregnant human in a manner that avoids unnecessary treatment of preeclampsia based on the urine levels of complexes detected in step c) and step d) in the pregnant human.
地址 Rochester MN US